H. Lundbeck A/s

The Scripps Research Institute

Andreas Ritzen

Nikolay Khanzhin

Mario Rottlander

William Patrick Watson

Christian Wenzel Tornoe

Jan Kehler

Kyriacos Costa Nicolaou

Jacob Nielsen

Morten Langgård

John Paul Kilburn

Karl-Heinz Altmann

Mario Rottländer

Mohamed M Farah

Kenji Namoto

Trond Ulven

Morten Bang Norgaard

Mitsuru Shoji

Christian Wenzel Thornøe

This invention is directed to phenylimidazole derivatives having the formula I: 

Substituted imidazoles as PDE10A inhibitors

This invention is directed to compounds, which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula I. The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention also provides a method of treating a subject suffering from a drug addiction comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I.

Phenylimidazole derivatives as PDE10A enzyme inhibitors

The present invention relates to morpholine and thiomorpholine derivatives of the general formula I or pharmaceutically acceptable salts thereof and their use.

Substituted thiomorpholine derivatives

The present invention relates to thiomorpholine derivatives of formula I or pharmaceutically acceptable salts thereof and their use in treating seizure disorders, anxiety disorders, bipolar disorders, neuropathic pain disorders and migraine pain disorders. 

The present invention relates to aniline derivatives of the general formula I or pharmaceutically acceptable salts thereof and their use. 

Substituted p-diaminobenzene derivatives

The present invention relates to morpholine and thiomorpholine derivatives or the general formula I or pharmaceutically acceptable salts thereof and their use.

Substituted morpholine and thiomorpholine derivatives

The present invention concerns 1,2,4-triaminobenzene derivatives of the general formula I or pharmaceutically acceptable salts thereof and the use thereof.

1,2,4-Triaminobenzene derivatives useful for treating disorders of the central nervous system

The invention relates to cis- and trans-12, 13-cyclopropyl and 12,13-cyclobutyl epothilones of formula I to IV wherein Ar is a radical represented by the following structure: and the other radicals and symbols have the meanings as defined herein; to their chemical synthesis and biological evaluation; their use in the treatment of neoplastic diseases and to pharmaceutical preparations containing such compounds. The compounds described herein are potent tubulin polymerization promoters and cytotoxic agents.

Cyclopropyl and cyclobutyl epothilone analogs

Designed epoxide and cyclopropane epothilone analogs with substituted side-chains are disclosed and characterized with respect to their biological activities against a series of human cancer cell lines. Among the several bioactive analogs, the epothilone B analog with a thiomethyl thiazole ring stands out as the most potent.

Growing community of inventors

Vanlose, Denmark

Andreas Ritzen